MCRB

Seres Therapeutics Stock Price

29.11
0.00 (0.0%)
29.11
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Seres Therapeutics Inc MCRB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 29.11 07:00:00
Close Price Low Price High Price Open Price Previous Close
29.11
Bid Price Ask Price Spread News
28.00 30.37 2.37 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 29.11 USD

Seres Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.60B 89.29M 51.76M $ 34.51M $ - -1.31 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Seres Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MCRB Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week28.0830.9827.3429.61360,2951.033.67%
1 Month28.2935.02326.6430.72547,4690.822.9%
3 Months4.3035.0234.3024.532,946,37624.81576.98%
6 Months3.9535.0233.4120.311,727,52925.16636.96%
1 Year3.3235.0232.5218.25988,35925.79776.81%
3 Years9.7835.0232.0214.25494,00419.33197.65%
5 Years31.6944.512.0214.69440,028-2.58-8.14%

Seres Therapeutics Description

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.


Your Recent History
NASDAQ
MCRB
Seres Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.